7902 results about "Metabolite" patented technology

The present invention provides methods and compositions for improving plant health. In particular, application of dicamba or another substrate of DMO, or metabolites thereof including DCSA, to a plant confers tolerance to, or defense against, abiotic or biotic stresses such as oxidative stress including herbicide application, and plant disease, and enhances crop yield. Such application may be in combination with the application of another herbicide such as glyphosate.

The present invention provides methods and compositions for improving plant health. In particular, application of dicamba or another substrate of DMO, or metabolites thereof including DCSA, to a plant confers tolerance to, or defense against, abiotic or biotic stresses such as oxidative stress including herbicide application, and plant disease, and enhances crop yield. Such application may be in combination with the application of another herbicide such as glyphosate.

A multifunctional membrane is provided. The multifunctional membrane is suitable for use in an analyte sensor. In a particular application, the multifunctional membrane may be used in connection with an amperometric biosensor, such as a transcutaneous amperometric biosensor. Some functions of the membrane are associated with properties of membrane itself, which is comprised of crosslinked polymers containing heterocyclic nitrogen groups. For example, the membrane, by virtue of its polymeric composition, may regulate the flux of an analyte to a sensor. Such regulation generally improves the kinetic performance of the sensor over a broad range of analyte concentration. Other functions of the membrane are associated with functional components, such as a superoxide-dismutating / catalase catalyst, either in the form of an enzyme or an enzyme mimic, that can be bound to the scaffold provided by the membrane. The effect of any such enzyme or enzyme mimic is to lower the concentration of a metabolite, such as superoxide and / or hydrogen peroxide, in the immediate vicinity of the sensing layer of the biosensor. Lowering the concentrations of such metabolites, which are generally deleterious to the function of the sensor, generally protects or enhances biosensor integrity and performance. The membrane is thus an important tool for use in connection with analyte sensors, amperometric sensors, biosensors, and particularly, transcutaneous biosensors. A membrane-covered sensor and a method for making same are also provided.

A sensor is disclosed, for implantation within a blood vessel to monitor a substance in or property of blood. In one embodiment, the sensor detects nitric oxide or a nitric oxide metabolite. In another embodiment, other substances such as glutamate, aspartate, arginine, citrulline, acetylcholine, calcium, potassium, or dopamine are monitored. The sensor may be attached to a support structure such as a stent, guidewire, or catheter. In a further embodiment, a catheter is disclosed that extracts patient fluid to a sensor outside the body for monitoring a substance or property of the patient fluid. Methods are also disclosed.

Microneedle devices are provided for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner. The microneedle devices permit in vivo sensing or withdrawal of biological fluids from the body, particularly from or through the skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. The microneedle device includes one or more microneedles, preferably in a three-dimensional array, a substrate to which the microneedles are connected, and at least one collection chamber and / or sensor in communication with the microneedles. Preferred embodiments further include a means for inducing biological fluid to be drawn through the microneedles and into the collection chamber for analysis. In a preferred embodiment, this induction is accomplished by use of a pressure gradient, which can be created for example by selectively increasing the interior volume of the collection chamber, which includes an elastic or movable portion engaged to a rigid base. Preferred biological fluids for withdrawal and / or sensing include blood, lymph, interstitial fluid, and intracellular fluid. Examples of analytes in the biological fluid to be measured include glucose, cholesterol, bilirubin, creatine, metabolic enzymes, hemoglobin, heparin, clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, reproductive hormones, oxygen, pH, alcohol, tobacco metabolites, and illegal drugs.

An apparatus for the continuous measurement of glucose and lactate in interstitial fluids including a glucose measurement cell, an A / D conversion block, a memory block and a bi-directional communication between the interface block and an external calculation unit.

A method and apparatus for spectrophotometric in vivo monitoring of blood metabolites such as hemoglobin oxygen concentration at a plurality of different areas or regions on the same organ or test site on an ongoing basis, by applying a plurality of spectrophotometric sensors to a test subject at each of a corresponding plurality of testing sites and coupling each such sensor to a control and processing station, operating each of said sensors to spectrophotometrically irradiate a particular region within the test subject; detecting and receiving the light energy resulting from said spectrophotometric irradiation for each such region and conveying corresponding signals to said control and processing station, analyzing said conveyed signals to determine preselected blood metabolite data, and visually displaying the data so determined for each of a plurality of said areas or regions in a comparative manner.

A system is disclosed that extracts bodily fluid to a reaction chamber for monitoring a substance or property of the patient fluid. In one embodiment, a pump is used to advance the sample of bodily fluid through a filter to produce a filtrate. Another pump advances filtrate into the reaction chamber, while another pump advances reactant into the reaction chamber. A sensor in communication with the reaction chamber determines a concentration of nitric oxide or one of its metabolic products. Methods are also disclosed.

Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor alpha (TNF-alpha) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and / or treatment of restenosis.

A noninvasive or minimally invasive procedure and system for measuring blood glucose levels is disclosed. A set of photodiodes detects the fluorescence and reflectance of light energy emitted from one or more emitters, such as LEDs, into a patient's skin. In an embodiment, small molecule metabolite reporters (SMMRs) that bind to glucose are introduced to the measurement area to provide more easily detected fluorescence.

The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

A multifunctional membrane is provided. The multifunctional membrane is suitable for use in an analyte sensor. In a particular application, the multifunctional membrane may be used in connection with an amperometric biosensor, such as a transcutaneous amperometric biosensor. Some functions of the membrane are associated with properties of membrane itself, which is comprised of crosslinked polymers containing heterocyclic nitrogen groups. For example, the membrane, by virtue of its polymeric composition, may regulate the flux of an analyte to a sensor. Such regulation generally improves the kinetic performance of the sensor over a broad range of analyte concentration. Other functions of the membrane are associated with functional components, such as a superoxide-dismutating / catalase catalyst, either in the form of an enzyme or an enzyme mimic, that can be bound to the scaffold provided by the membrane. The effect of any such enzyme or enzyme mimic is to lower the concentration of a metabolite, such as superoxide and / or hydrogen peroxide, in the immediate vicinity of the sensing layer of the biosensor. Lowering the concentrations of such metabolites, which are generally deleterious to the function of the sensor, generally protects or enhances biosensor integrity and performance. The membrane is thus an important tool for use in connection with analyte sensors, amperometric sensors, biosensors, and particularly, transcutaneous biosensors. A membrane-covered sensor and a method for making same are also provided.

Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites.

The present invention describes changes in bacterial gastrointestinal, cutaneous and nasal microbiota associated various mammalian medical conditions. Described are diagnostic tests that arise from combining phylogenetic information about the families, genus, and species of the microbiome and their relative abundance with the metabolic information contained in the metatranscriptome to determine the presence and absence of a disease or medical condition. Provided are compositions of bacteria, co-cultures of bacteria and a carrier for use in treating the disclosed medical conditions. The described compositions restore or correct disease- or medical condition-related imbalances in the microbiome profile with culture-conditioned formulations in which the transcriptome activity of the administered organisms is optimized. Alternatively, formulations of metabolites that drive changes in the metatranscriptome native to the mammal that treat disease or a medical condition or restore health are taught.

A device, method and process for three-dimensional spatial localization and functional interconnection of the same or different types of cells. The two or three-dimensional device comprising multiple layers containing wells for cell deposition where both the wells and layers are interconnected through microfluidic channels. A process for fabricating the three-dimensional device and a method for depositing different types of cells within the device in a functional interdependent spatial orientation thereby mimicking physiological functions. The device is useful for diagnostic assays, determination of dysfunction of certain cells in the system, quantification of production of cellular proteins, metabolites, hormones or other cellular products, for organ or tissue replacement, for co-culturing different cells, for testing pharmaceutical agents and as a bioreactor for production of biologicals.

The invention provides methods employing iterative cycles of recombination and selection / screening for evolution of whole cells and organisms toward acquisition of desired properties Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and / or secretion of proteins and secondary metabolites.

Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and / or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes (at physiologic pH, but can become active toward cell membranes if the environment is acidified below ca. pH 6.8), coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and / or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and / or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and / or electrophereis can also be used with the disrupting agents.

A portable peritoneal dialysis system for a patient includes an inlet port for providing inflow to the patient's peritoneal cavity, an outlet port for providing outflow from the patient's peritoneal cavity, and a volume of dialysate for flow into and out of the patient's peritoneal cavity, thereby removing from the dialysate uremic waste metabolites that have diffused into the dialysate. The portable peritoneal dialysis system also includes a closed liquid flow loop, including a pump, for flowing the dialysate into and out of the patient's peritoneal cavity, and an organic- and phosphate-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing organic compounds and phosphate from dialysate removed from the patient's peritoneal cavity. The portable peritoneal dialysis system further includes a urea- and ammonia-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing urea and ammonia from dialysate removed from the patient's peritoneal cavity, the material being packed around semi-permeable hollow fibers with interior fiber walls that reject cations, thereby retaining cations in the dialysate.

The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.

The present invention relates to a probe compound that can comprise any substrate or metabolite of an enzymatic reaction in addition to an indicator component, such as, for example, a fluorescence dye, or the like. Moreover, the present invention relates to means for detecting enzymes in form of an array, which comprises any number of probe compounds of the invention which each comprise a different metabolite of interconnected metabolites representing the central pathways in all forms of life. Moreover, the present invention relates to a method for detecting enzymes involving the application of cell extracts or the like to the array of the invention which leads to reproducible enzymatic reactions with the substrates. These specific enzymatic reactions trigger the indicator (e.g. a fluorescence signal) and bind the enzymes to the respective cognate substrates. Moreover, the invention relates to means for isolating enzymes in form of nanoparticles coated with the probe compound of the invention. The immobilisation of the cognate substrates or metabolites on the surface of nanoparticles by means of the probe compounds allows capturing and isolating the respective enzyme, e.g. for subsequent sequencing.

The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)p  Iwhere one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.

Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).

The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.

The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and / or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.

The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a cell-cycle dependent biological agent, a schedule-dependent biological agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1 / S interphase, S-phase, G2 / M interface or M-phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention.

This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood glucose concentration levels based upon the in vivo measurement of one or more biologically active molecules found in skin.